Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1416 - Predictive value of vascular endothelial growth factor A (VEGF-A) for bevacizumab-based treatments across advanced cancers: a meta-analysis based on eight phase III randomized control trials involving 4,523 patients


10 Oct 2016


Poster display


Shiyan Tang


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


S. Tang1, Y. Zhang1, W. Liang2, J. He1

Author affiliations

  • 1 Department Of Thoracic Oncology, The 1st Affiliated Hospital of Guangzhou Medical University, 510120 - Guangzhou/CN
  • 2 Department Of Thoracic Oncology, The 1st Affiliated Hospital of Guangzhou Medical University, 510000 - Guangzhou/CN


Abstract 1416


Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be beneficial for patients with advanced cancer in phase III randomized control trials which had associated biomarker analyses. We aim to evaluate the predictive value of circulating VEGF-A on patient survival in these studies.


PubMed was searched for eligible trials from the date of inception to 31st December, 2015. Based on the median circulating level of VEGF-A in each trial, we conducted a meta-analysis with random-effect model to estimate the treatment effects between bevacizumab-based treatments and treatments without bevacizumab on progression-free survival (PFS) and overall survival (OS). Interaction test was used to examine the predictive value.


Eight studies were included, involving 4,523 patients analyzed with VEGF-A level. Patients following bevacizumab-based treatments had significantly prolonged PFS regardless of VEGF-A level (high:HR = 0.70 [95 % CI 0.63-0.77], P 


There is still insufficient evidence to support the use of VEGF-A as a predictive biomarker for bevacizumab-based treatment in advanced cancers.

Clinical trial identification

Legal entity responsible for the study



The First Affiliated Hospital of Guangzhou Medical University


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings